Results 11 to 20 of about 2,582,733 (281)

Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells [PDF]

Frontiers in Cell and Developmental Biology, 2021
Triple-negative breast cancer is a heterogeneous disease that still lacks specific therapeutic approaches. The identification of new biomarkers, predictive of the disease’s aggressiveness and pharmacological response, is a challenge for a more tailored ...
Marzia Di Donato, Giovanni Galasso, Pia Giovannelli, Antonio A. Sinisi, Antimo Migliaccio, Gabriella Castoria   +5 more
doaj   +4 more sources

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. [PDF]

Ann Oncol, 2020
Sarcomas are a heterogeneous group of malignancies with mesenchymal lineage differentiation. The discovery of neurotrophic tyrosine receptor kinase (NTRK) gene fusions as tissue-agnostic oncogenic drivers has led to new personalized therapies for a ...
Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, George S, Gronchi A, Haas RL, Hindi N, Hohenberger P, Joensuu H, Jones RL, Judson I, Kang YK, Kawai A, Lazar AJ, Le Cesne A, Maestro R, Maki RG, Martín J, Patel S, Penault-Llorca F, Premanand Raut C, Rutkowski P, Safwat A, Sbaraglia M, Schaefer IM, Shen L, Serrano C, Schöffski P, Stacchiotti S, Sundby Hall K, Tap WD, Thomas DM, Trent J, Valverde C, van der Graaf WTA, von Mehren M, Wagner A, Wardelmann E, Naito Y, Zalcberg J, Blay JY.   +47 more
europepmc   +9 more sources

Tropomyosin receptor kinase inhibitors in the management of sarcomas [PDF]

Current Opinion in Oncology, 2020
Purpose of review Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas are rare and there is a significant challenge in identifying patients with sarcomas harbouring TRK fusions in
Wilding, CP, Loong, HH, Huang, PH, Jones, RL   +3 more
openaire   +7 more sources

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer [PDF]

Case Reports in Oncology, 2023
In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these ...
Lorenz Frehner, Simon Haefliger, Ferdinando Cerciello, Tobias Grob, Sabine Schmid   +4 more
doaj   +3 more sources

Pyrazolo[1,5-a]pyrimidine as a Prominent Framework for Tropomyosin Receptor Kinase (Trk) Inhibitors—Synthetic Strategies and SAR Insights [PDF]

Molecules
Tropomyosin receptor kinases (Trks) are transmembrane receptor tyrosine kinases named TrkA, TrkB, and TrkC and encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively.
Amol T. Mahajan, Shivani, Ashok Kumar Datusalia, Carmine Coluccini, Paolo Coghi, Sandeep Chaudhary   +5 more
doaj   +2 more sources

Somatic rearrangement of the tropomyosin-receptor-kinase (trk) oncogene is rare in gastrointestinal cancer [PDF]

British Journal of Cancer, 1988
Somatic rearrangement of the tropomyosin-receptor-kinase ( trk ) oncogene is rare in gastrointestinal ...
M.F. Fey, SL Thein
openalex   +5 more sources

A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma [PDF]

PeerJ, 2019
Neurotrophic receptor tyrosine kinase 2 (NTRK2) is a member of the tropomyosin receptor kinase family associated with the tumor development. However, the detailed function of NTRK2 in lung cancer, especially in lung adenocarcinoma (LUAD), is still not ...
Xiang Wang, Zhijie Xu, Xi Chen, Xinxin Ren, Jie Wei, Shuyi Zhou, Xue Yang, Shuangshuang Zeng, Long Qian, Geting Wu, Zhicheng Gong, Yuanliang Yan   +11 more
doaj   +5 more sources

Effects of Tetrahydrocannabinol and Cannabidiol on Brain-Derived Neurotrophic Factor and Tropomyosin Receptor Kinase B Expression in the Adolescent Hippocampus. [PDF]

Cannabis Cannabinoid Res, 2023
Winstone J, Shafique H, Clemmer ME, Mackie K, Wager-Miller J.   +4 more
europepmc   +3 more sources

Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application [PDF]

Journal of Medicinal Chemistry, 2018
The use of kinase-directed precision medicine has been heavily pursued since the discovery and development of imatinib. Annually, it is estimated that around ∼20 000 new cases of tropomyosin receptor kinase (TRK) cancers are diagnosed, with the majority of cases exhibiting a TRK genomic rearrangement. In this Perspective, we discuss current development
Wei Yan, Naga Rajiv Lakkaniga, Francesca Carlomagno, Massimo Santoro, Neil Q. McDonald, Fengping Lv, Gunaganti Naresh, Brendan Frett, Hong‐yu Li   +8 more
openalex   +7 more sources

Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer. [PDF]

Ann Oncol, 2019
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and ...
Amatu A, Sartore-Bianchi A, Bencardino K, Pizzutilo EG, Tosi F, Siena S.   +5 more
europepmc   +5 more sources